Lupus Landmark Study: A Prospective Registry and Biorepository

Launched by LUPUS RESEARCH ALLIANCE · Jul 5, 2023

Keywords

ClinConnect Summary

The Lupus Landmark Study is a clinical trial designed to gather important information about systemic lupus erythematosus (SLE), including its effects on the kidneys (lupus nephritis) and the brain (neuropsychiatric SLE). The study will create a registry and biorepository, which means it will collect and store health data and biological samples from participants. This information will help researchers better understand lupus and develop new treatments in the future.

To participate in this study, individuals must be at least 18 years old and meet specific criteria for having lupus, as determined by established medical guidelines. Participants will need to understand and agree to the study procedures and be able to attend scheduled visits. Those who are pregnant or unable to provide consent will not be eligible. If you join the study, you can expect to contribute valuable information that may help others with lupus in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Able to understand and comply with study procedures and voluntarily sign a written informed consent document
• • Age 18 years or older at the time of enrollment
• * Fulfill criteria for SLE based on one or more of the following classifications systems:
• • Systemic Lupus Erythematosus International Collaborating Clinic (SLICC) 2012 criteria; European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 criteria; 1997 revised ACR criteria; or Lupus is present per clinical assessment.
• Exclusion Criteria:
• • Not able to obtain consent
• • Not able to meet protocol visit requirements
• • Pregnant at the time of enrollment